Daniel Otzen receives funding for Parkinson's disease research project
Aiming to find inhibitors or blockers to treat Parkinson's disease.
Daniel Otzen has received a grant of 414.720 € within the Joint Programme in Neurodegenerative Diseases (JPND) for the project:
"Alpha-synuclein pathology propagation in Parkinson’s disease and quest for novel protective strategies."
This project will further the understanding for the group of researchers, on how the aggregation process is initiated in the body and how aggregated Alpha-synuclein (a-syn), with or without post-translational modifications (PTMs), spreads between cells/neurons; and whether small chemical molecules or biological agents, such as a-syn species-specific antibodies, can inhibit or block these processes opening new avenues to treat the disease. The findings and novel targets identified in this program, in the context of Parkinson's disease (PD), may also be applicable to other neurodegenerative diseases.
For more information please contact:
Daniel Otzen email@example.com
Gustav Wieds Vej 14
Building 1592, 224
8000 Aarhus C